Biora Therapeutics is a biotechnology company. Co. supports patients and physicians during patients' life decisions with its suite of molecular tests, including: Innatal Prenatal Screen, which is a noninvasive prenatal test provided to women early in pregnancy to screen for risk of fetal chromosomal conditions, such as Down syndrome and sex chromosome disorders; and Resura Prenatal Test for Monogenic Disease, which is a test for monogenic diseases. Co.'s precision medicine development pipeline includes Recoverable Sampling System, which is an ingestible capsule platform designed to enable the collection, preservation, and analysis of samples. The BIOR stock yearly return is shown above.
The yearly return on the BIOR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the BIOR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|